Dynavax Technologies Intrinsic Stock Value – Beating the Market with Dynavax Technologies Corporation Stock: What Shareholders Need to Know
April 27, 2023
Trending News 🌧️
Dynavax Technologies ($NASDAQ:DVAX) Corporation is a biopharmaceutical company dedicated to unlocking the potential of the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company is focused on developing novel vaccines and immuno-oncology therapeutics, as well as developing TLR-based product candidates for asthma, allergies, and infectious diseases. As a shareholder, now is a great time to take advantage of the current market conditions and purchase Dynavax Technologies Corporation stock at its closing price of $10.81 in the latest session. This is lower than the previous closing price of $10.93, making it an ideal time to invest. Dynavax Technologies Corporation has recently seen many successes, such as receiving approval for their hepatitis B vaccine, Heplisav-B, from the US Food and Drug Administration and the European Medicines Agency.
Additionally, the company has a number of clinical trials in progress for its various diseases, providing potential further upside in the stock price. Overall, Dynavax Technologies Corporation is a promising stock with several growth catalysts that makes it an attractive buy for investors. With its current price below its previous closing price, as well as its strong performance over the past month, now is a great time for investors to consider adding this stock to their portfolio.
Price History
Monday was a disappointing day for Dynavax Technologies Corporation shareholders, as the stock opened at $11.0 and closed at $10.9, down by 0.7% from the previous closing price of $11.0. This means that shareholders who had invested in the company’s stock were seeing diminishing returns on their investments.
However, despite this short-term setback, Dynavax Technologies Corporation’s long-term prospects remain strong. In order to make the most of their investments, shareholders should look at the company’s record of success and its future plans. Dynavax Technologies Corporation has a history of successful products and services which have consistently beaten market expectations. This includes the company’s proprietary HEPLISAV-B vaccine, which has been approved by the FDA and is now being used by millions of people around the world. Furthermore, Dynavax Technologies Corporation recently announced a collaboration with Merck to develop a new vaccine for cancer treatment. The company also has a strong financial position, with a strong balance sheet and steady cash flow. This means that the company’s stock is less likely to be affected by external factors such as market volatility or economic downturns. Ultimately, Dynavax Technologies Corporation is a strong investment for shareholders who are looking to make the most out of their investments. When considering investing in the company’s stock, shareholders should look at the company’s track record of success and its future plans in order to ensure their investments are profitable. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Dynavax Technologies. More…
| Total Revenues | Net Income | Net Margin |
| 722.68 | 292.87 | 40.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Dynavax Technologies. More…
| Operations | Investing | Financing |
| 62.72 | -316 | 19.52 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Dynavax Technologies. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 985.85 | 404.84 | 4.55 |
Key Ratios Snapshot
Some of the financial key ratios for Dynavax Technologies are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 173.8% | – | 41.7% |
| FCF Margin | ROE | ROA |
| 7.7% | 34.8% | 19.1% |
Analysis – Dynavax Technologies Intrinsic Stock Value
At GoodWhale, we conducted an analysis of DYNAVAX TECHNOLOGIES‘s financials and concluded that the fair value of their share is around $33.5. This value was determined using our proprietary Valuation Line. At the time of writing, DYNAVAX TECHNOLOGIES stock is being traded at a price of $10.9, indicating that it is undervalued by 67.5%. We believe that investors could benefit from purchasing their shares at the current price and may see a return on their investment in the future. More…
Peers
The market for Dynavax Technologies Corp is quite competitive. The company’s main competitors are Foresee Pharmaceuticals Co Ltd, Aeolus Pharmaceuticals Inc, and Kala Pharmaceuticals Inc. All of these companies are vying for a share of the market, and each has its own strengths and weaknesses. Dynavax Technologies Corp must keep an eye on all of its competitors in order to stay ahead in the market.
– Foresee Pharmaceuticals Co Ltd ($TPEX:6576)
Foresee Pharmaceuticals Co Ltd is a pharmaceutical company with a market cap of 8.77B as of 2022. The company has a Return on Equity of -22.28%. The company focuses on the development and commercialization of innovative drugs for the treatment of cancer and other diseases. The company’s products include F-76, a phase III clinical candidate for the treatment of ovarian cancer; and F-288, a phase II clinical candidate for the treatment of solid tumors. Foresee Pharmaceuticals Co Ltd was founded in 2007 and is headquartered in Taipei, Taiwan.
– Aeolus Pharmaceuticals Inc ($OTCPK:AOLS)
Aeolus Pharmaceuticals Inc is a pharmaceutical company that focuses on the development of treatments for a variety of conditions. The company’s market cap is $167.29k and its ROE is -383.62%. Aeolus Pharmaceuticals Inc’s main product is a treatment for a condition called idiopathic pulmonary fibrosis. The company is also developing treatments for other conditions, including cancer and Alzheimer’s disease.
– Kala Pharmaceuticals Inc ($NASDAQ:KALA)
Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of eye diseases. The company’s lead product candidate, KPI-121, is a topical ocular formulation of loteprednol etabonate in development for the treatment of pain and inflammation associated with ocular surgery. Kala Pharmaceuticals Inc has a market cap of 7.69M as of 2022, a Return on Equity of 435.55%. The company’s focus on the development and commercialization of therapies for the treatment of eye diseases makes it a promising investment for those interested in the healthcare sector.
Summary
Investing in Dynavax Technologies Corporation stock can be a great way to beat the market. Shareholders should consider conducting thorough analysis of the company and industry, researching financial statements and assessing the competitive landscape before investing.
Additionally, staying current on news and tracking trends can be beneficial to making informed investment decisions. It is essential to monitor the performance of the stock, keep a close eye on global factors that could affect the stock, and be aware of potential risks when investing. Having a long-term strategy and understanding the fundamentals of the stock are key in maximizing profits from investing in Dynavax Technologies Corporation.
